Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Barclays analyst Luke Sergott has maintained an Overweight rating on Quest Diagnostics (NYSE: DGX) and increased the price target from $250 to $260. This adjustment reflects a positive outlook on the company's performance.